Announcements Trials

Browse Landscape

Phase

Phase 2 5 Phase 3 2 Phase 4 1 Phase 1/2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Hepatocellular 5 Triple Negative Breast Neoplasms 4 Neoplasms 2 Esophageal Squamous Cell Carcinoma 2 Biliary Tract Neoplasms 2 Advanced Gastric Cancer 2 Urinary Bladder Neoplasms 1 Thoracic Neoplasms 1 Stomach Neoplasms 1 Respiratory Tract Diseases 1 Recurrence 1 Rectal Neoplasms 1 Pyloric Stenosis, Hypertrophic 1 Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1 Pleural Effusion, Malignant 1 Pancreatic Neoplasms 1 Lymphoma, T-Cell, Peripheral 1 Lymphoma, Non-Hodgkin 1 Lymphoma, Large B-Cell, Diffuse 1 Lung Neoplasms 1 Lung Diseases 1 Locally Advanced or Metastatic Solid Tumors 1 Locally Advanced or Metastatic Gastric Adenocarcinoma 1 Hepatic Metastasis of Colorectal Cancer 1 Esophageal Neoplasms 1 Disease Progression 1 Colorectal Neoplasms 1 Colorectal Cancer Recurrent 1 Carcinoma, Non-Small-Cell Lung 1 CRC 1

Interventions

pembrolizumab 37 Carboplatin 26 Radiotherapy 23 Cisplatin 19 Paclitaxel 18 Erlotinib Hydrochloride 18 Docetaxel 15 Gemcitabine 14 Pemetrexed 13 Etoposide 12 osimertinib 11 Nivolumab 11 durvalumab 9 atezolizumab 9 Radiosurgery 8 Magnetic Resonance Spectroscopy 8 Cetuximab 7 Specimen Handling 6 Cyclophosphamide 6 130-nm albumin-bound paclitaxel 6 Taxes 5 Immunoglobulin G 5 Gefitinib 5 Biopsy 5 Bevacizumab 5 fludarabine 4 Radiation 4 Ipilimumab 4 Disulfides 4 Albumin-Bound Paclitaxel 4

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × Lung Neoplasms × camrelizumab × Clear all

NCT04201990 2019-12-17

CCA-MPLC

Guangzhou Institute of Respiratory Disease

Phase 1/2 Unknown

Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡